Alexandra Glucksmann
Director/Board Member at REGENXBIO INC.
Net worth: 48 341 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kenneth Mills | M | 49 | 16 years | |
| Richard Simon | M | - |
Sensorium Therapeutics, Inc.
 Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | - |
| Sebastian Nijman | M | - |
Scenic Biotech BV
 Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | 7 years |
| Vit Vasista | M | 56 | 15 years | |
| George Migausky | M | 69 | 3 years | |
| Akshay Vaishnaw | M | 61 | 8 years | |
| Alex Simon | M | - |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | - |
| Jean Bennett | M | 69 | 3 years | |
| Shiva G. Fritsch | F | - | 7 years | |
| Jennifer Zachary | F | 46 | 2 years | |
| Thijn Brummelkamp | M | - |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | 7 years |
| Ram Palanki | M | 48 | 6 years | |
| Allan Fox | M | 76 | 15 years | |
| Daniel Tassé | M | 64 | 8 years | |
| Cornelis Alexander Izeboud | M | 53 |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | - |
| Robert Rosenthal | M | 67 |
Taconic Biosciences, Inc.
 Taconic Biosciences, Inc. Agricultural Commodities/MillingProcess Industries Taconic Biosciences, Inc. provides research rodents and related products and services. It offers monoclonal antibody production, drug safety testing and other services. The firm also provides contract breeding solutions, animal models, Taconic transgenic exchange, custom model generation, contract research solutions, and research services. The company was founded by Robert K. Phelan in 1949 and is headquartered in Rensselaer, NY. | 10 years |
| David Stump | M | 74 | 9 years | |
| Argeris Karabelas | M | 71 | 9 years | |
| Curran Simpson | M | 62 | 9 years | |
| Mark J. Ratain | M | 69 |
The University of Chicago
| 41 years |
| David Southwell | M | 63 |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | 1 years |
| Stephan Christgau | M | 60 |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | - |
| Roel Bulthuis | M | - |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | 5 years |
| Dana Fisher Cormack | M | - | 3 years | |
| Stephen Pakola | M | 55 | 5 years | |
| Philippe Dro | M | 61 |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | - |
| Ryan Katz | M | - |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | 2 years |
| Richard P. Strubel | M | 84 |
The University of Chicago
| 37 years |
| Stéphane Verdood | M | - |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | - |
| Graeme I. Bell | M | - |
The University of Chicago
| 38 years |
| F. Gary Toback | M | - |
The University of Chicago
| 39 years |
| Edward van Wezel | M | - |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | - |
| Jerome W. Jackson | M | - | 9 years | |
| Michelle LeBeau | M | 70 |
The University of Chicago
| 38 years |
| Olivier Danos | M | 66 | 7 years | |
| Simone Botti | M | - |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | - |
| Nick Dixon-Clegg | M | - |
Scenic Biotech BV
Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alan Crane | M | 60 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.
Cerulean Pharma, Inc.
 Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 5 years |
| Christopher Guiffre | M | 56 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | - |
| Ram Sasisekharan | M | 58 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 9 years |
| Katrine Bosley | F | 56 | 5 years | |
| Oliver Fetzer | M | 60 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 5 years |
| Kevin Bitterman | M | 47 | 5 years | |
| Michael Frankel | M | 56 |
The University of Chicago
| 9 years |
| Mark Levin | M | 73 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 12 years |
| Deborah Dunsire | M | 61 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 8 years |
| Anna Protopapas | F | 59 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 17 years |
| Daniel J. Young | M | - |
The University of Chicago
| 4 years |
| Mark Phelan | M | 55 |
The University of Chicago
| 3 years |
| Richard C. Wirthlin | M | - |
The University of Chicago
| 3 years |
| George Esgro | M | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 1 years |
| Ervin E. Shindell | M | 65 |
The University of Chicago
| - |
| Mark Nydam | M | - |
The University of Chicago
| 3 years |
| James Liang | M | 66 |
The University of Chicago
| 2 years |
| Peter F. Smith | M | 66 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | - |
| Igal Litovsky | M | - |
The University of Chicago
| 4 years |
| Daniel Abdun-Nabi | M | 69 | 6 years | |
| Raju S. Kucherlapati | M | 81 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | - |
| Lisa Adler | F | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | - |
| Bill Bergman | M | - |
The University of Chicago
| 3 years |
| Todd Shegog | M | 59 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 16 years |
| Chang-Jin Moon | M | 71 |
The University of Chicago
| 2 years |
| Alok Gaur | M | - |
The University of Chicago
| 6 years |
| Jeremy Feigelson | M | - |
The University of Chicago
| 3 years |
| Joseph Werne | M | - |
The University of Chicago
| 5 years |
| Laura Burakreis | F | - |
The University of Chicago
| 6 years |
| Sara Garon Berl | F | - | 8 years | |
| Carla N. Taylor | F | - |
The University of Chicago
| 6 years |
| Stanley Ryan | M | 62 |
The University of Chicago
| 2 years |
| Boris Nikolic | M | 54 | 3 years | |
| Catherine Stehman-Breen | M | 61 |
The University of Chicago
| 3 years |
| Andrew Hack | M | 50 | 4 years | |
| Nancy Simonian | M | 63 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 10 years |
| Steve Hall | M | 69 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 6 years |
| Kevin K. Pfeffer | M | - |
The University of Chicago
| 6 years |
| John F. Madden | M | 63 |
The University of Chicago
| 7 years |
| Luke Beshar | M | 65 | 6 years | |
| Marsha Fanucci | F | 70 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 9 years |
| Laurie Keating | F | 70 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 10 years |
| Kimi Iguchi | F | 61 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | - |
| John Bishop | M | 62 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 4 years |
| William C. Stern | M | 60 |
The University of Chicago
| 3 years |
| Donald Hayden | M | 68 | 7 years | |
| Douglas Cole | M | 63 | 4 years | |
| Kevin Starr | M | 61 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 4 years |
| Michael Anthony Duffy | M | - |
The University of Chicago
| 8 years |
| Andrew Alford | M | - |
The University of Chicago
| 6 years |
| Bruce Eaton | M | 70 | 9 years | |
| John Ettelson | M | - |
The University of Chicago
| 4 years |
| David Abramson | M | - |
The University of Chicago
| 2 years |
| Jim Sanderson | M | - |
The University of Chicago
| 4 years |
| Gary K. Kilberg | M | - |
The University of Chicago
| 6 years |
| Alexis Borisy | M | 52 | 5 years | |
| Gary R. Doernhoefer | M | 66 |
The University of Chicago
| 4 years |
| Lee R. Brettman | M | 77 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 2 years |
| Karen L. Roberts | F | 67 |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | 5 years |
| Jeffrey Gulcher | M | - |
The University of Chicago
| 7 years |
| James Rasulo | M | 68 |
The University of Chicago
| 4 years |
| Luis Alberto Mañas Antón | M | 65 |
The University of Chicago
| 4 years |
| Michael Booth | M | - |
The University of Chicago
| 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 90 | 90.00% |
| Netherlands | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alexandra Glucksmann
- Personal Network